Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure, angina (chest pain), and chronic heart failure
Cadila Pharmaceuticals has launched Biscado (Bisoprolol), marking its foray into the dynamic and fast-growing field of beta-blocker therapy, a vital component in the treatment of cardiovascular diseases.
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure, angina (chest pain), and chronic heart failure. Reducing heart rate and blood pressure, eases the strain on the heart and has been shown to significantly improve survival and reduce hospitalisations in heart failure patients.
“India is at the epicentre of a cardiovascular epidemic, and elevated heart rate is a major modifiable risk factor. With the launch of Biscado, Cadila Pharmaceuticals brings a powerful, clinically proven solution to physicians and patients right when it is needed most,” said a senior spokesperson at Cadila Pharmaceuticals.
